Advertisement

Topics

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

19:00 EST 12 Feb 2019 | EHEALTHNEWS.EU

Boehringer IngelheimBoehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada.

Original Article: Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...